Pharmacopeia Inc

Pharmacopeia — Investor Presentation (May 2008)

11 slides from Pharmacopeia's investor presentation, May 16, 2008

  1. Slide 1: PS433540 Phase 2a Study Results

    Discovering excellence, driving clinical successTM Investor Presentation PS433540 Phase 2a Study Results May 16, 2008

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements . This presentation and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which ex

  3. Slide 3: Dual Acting Receptor Antagonist - DARA

    Dual Acting Receptor Antagonist - DARA • First-in-class antagonist at both the AT1 and ETA receptors • Simultaneously blocks the actions of ET-1 and AII • Multiple potential clinical indications S NH O O O N Me Me N N O Me O Me PS433540

  4. Slide 4: Dual Activity In Vivo

    Dual Activity In Vivo Big ET-1 ED50 = 7.6 mg/kg Vehicle-adjusted % Inhibition (normalized) 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 1 10 100 Angiotensin II ED50 = 0.9 mg/kg Vehicle-adjusted % Inhibition (normalized) 0 10 20 30 40 50 60 70 80 90 100 Dose (mg/kg) 0.1 1.0 10.0 100.0 Pharmacologica

  5. Slide 5: Efficacy in Rat Hypertension Models

    Efficacy in Rat Hypertension Models Hours after dosing 0 2 4 6 8 10 12 14 16 18 20 22 24 Mean arterial pressure mm Hg 0 120 130 140 150 160 170 Vehicle n=12 Vanlev 50µmol/kg n=7 DARA 50µmol/kg n=7 Vanlev 100µmol/kg n=10 DARA100µmol/kg n=11 SHR – Single Oral Dose (BMS Data) Hours after dosing 0 2 4 6

  6. Slide 6: PS433540 SAD Results

    PS433540 SAD Results AUC(0-inf) versus Dose for 0-48 Hour Concentrations AUC(0-inf) (ng*h/mL) (Mean+SE) 5000 15000 25000 35000 45000 55000 65000 75000 85000 95000 105000 115000 125000 Dose (mg) 0 100 200 300 400 500 600 700 800 900 1000 -- -- -- -- -- -- -- -- -- -- -- Safety •Well tolerated at all

  7. Slide 7: AII Challenge Results

    AII Challenge results SBP – Dose dependent AII blockade All doses inhibited the AII pressor response Differences vs placebo all statistically significant 250mg, 500mg and irbesartan 300mg: complete blockade for 24hours. Presented at ASCPT 2008 SBP Mean % Inhibition 230 210 190 170 150 130 110 90 70

  8. Slide 8: Plasma Renin Activity in MAD Study

    Plasma Renin Activity in MAD study Plasma Renin Activity -5 5 15 25 0 2 4 8 12 24 0 2 4 8 12 24 Absolute Change From Baseline (ng/mL/hr) placebo PS433540 100mg PS 433540 250mg PS433540 500mg PS433540 1000mg Hours Day 1 Hours Day 15 # * ** p p p * * # ** P vs placebo <0.0001 P vs placebo <0.005 P vs

  9. Slide 9: Supine Systolic Blood Pressure

    Supine Systolic Blood Pressure -20 -15 -10 -5 0 5 0 2 4 8 12 24 0 2 4 8 12 24 Absolute Change From Baseline mmHg placebo PS433540 100mg PS 433540 250mg PS433540 500mg PS433540 1000mg Hours Day 1 Hours Day 15 Systolic BP in MAD Study

  10. Slide 10: Phase Development

    Phase 2 Development Phase 2b -006 Phase 2a -008 Study 12-week, double-blind placebo controlled study (200 mg, 400 mg, 800 mg, 300 mg irbesartan) SBP and DBP Approximately 375 subjects Stage I&II hypertensive subjects Dose related efficacy and safety Comparative efficacy vs irbesartan 4-week, double-

  11. Slide 11: Joel M. Neutel, MD

    Joel M. Neutel, MD • Principal Investigator, Phase 2a Study of PS433540 and Member Pharmacopeia Clinical Advisory Board • Associate Professor of Medicine, Department of Medicine University of California - Irvine Campus • Medical Director of Clinical Pharmacology, Orange County Research Center • Dire

Pharmacopeia — Investor Presentation (May 2008) on 6ix